Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Bristol-Myers Squibb/Otsuka’s Abilify is the branded agent with the highest patient share in schizophrenia, according to U.S. psychiatrists surveyed... Learn More
Join us live on December 10, 2014... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
New Country Archetypes Model + Executive Briefing
Country Archetypes: A guided tour of market access around the world
December 3, 2014
PCSK9 and CETP Inhibitors Are Set to Transform the Dyslipidemia Market
December 2, 2014
The Type 2 Diabetes Population will Continue to Expand in China, But Patient Access to Novel Non-Insulin Treatments is Sub-Optimal
November 24, 2014
Surveyed European Oncologists Indicate that Predictive Biomarkers that Identify Patients Most Likely to Respond to Therapies Are a Clear Advantage for Costly Oncology Drugs
U.S. Claims Data Show That Biogen Idec’s Tecfidera Captured Nearly Half of Second-Line Share Among Newly Diagnosed Multiple Sclerosis Patients
EU5 Market Access Opportunities and Challenges for Current and Emerging RA Agents Amid the Launches of Oral Jak Inhibitors and Biosimilars.
Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation... Read More
What Market Access Levers and Barriers Will Emerging Biologics for SLE Face in Europe? A Study of EU5 Prescribers and Payers
In 2011, GlaxoSmithKline’s Benlysta became the first biological treatment ever approved for systemic lupus... Read More
Malignant Melanoma - 2014
The poor prognosis of advanced malignant melanoma (melanoma) patients means that there is a significant need for... Read More